Viridian Therapeutics (VRDN) Stock Forecast & Price Target

Viridian Therapeutics is expected to experience significant growth in revenue starting in 2027, with potential peak revenue of over $500 million by 2028. The company's differentiated humanized monoclonal antibody targeting IGF-1R may give them a second-mover advantage in treating thyroid eye disease and they are also developing a subcutaneous administration option with a longer half-life, which could potentially expand their market reach. With a strong clinical development program and a market shaping up as a Tepezza/VRDN duopoly, the company has a favorable outlook for future success and potential revenue growth.

Viridian Therapeutics is a clinical-stage biopharmaceutical company that is developing two product candidates to treat thyroid eye disease, veligrotug and elegrobart. The company recently launched Lumvoa and has achieved positive early metrics, however, with minimal expected revenue for the next few years, upcoming catalysts will be crucial for maintaining pipeline momentum. Despite the potential in the thyroid eye disease market, there are concerns around clinical trial conduct and data transparency, as well as the lack of diversity in the management team. Additionally, the success of veligrotug is critical for the company's future, and any failure to gain approval could significantly impact its stock value.